aibioEVT Evotec SE
Evotec (EVT) news
Evotec SE is a public biotech or pharmaceutical company listed on XETR under the ticker EVT, recorded under Germany. The directory classifies it as Biopharma / pharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest Evotec news
We have not published a story on Evotec yet. When there is news, it will appear here.
What Evotec does
Evotec SE is a German company that describes drug discovery, preclinical development and manufacturing as a seamless continuum. It offers access to its platforms to pharmaceutical and biotechnology partners across discovery services, development and manufacturing services, and ADME-Tox solutions. Its biologics operations, operated by JEB, cover discovery, process development and manufacturing. The company says it works in oncology, central nervous system disorders, cardiovascular-renal disorders, immune and inflammatory diseases, infectious diseases, fibrotic and respiratory diseases, women's health, rare diseases and animal health. Its new strategy focuses on AI-driven innovation, molecular glue degraders and targeted protein degradation. A substantial majority of its partner revenues are based on fee-for-service or full-time equivalent arrangements, with milestone and royalty payments possible in co-development. As of December 2025, 62 active projects were partnered. Its partners range from leading pharmaceutical companies to small and large biotechnology companies and academic institutions. It also sold its dedicated Toulouse site to Sandoz AG, with final closing on December 5, 2025.
| Product or program | What it is | Stage |
|---|---|---|
| Discovery Services | Preclinical discovery services offered to pharmaceutical and biotechnology partners | |
| Development and Manufacturing Services | Preclinical development and biologics manufacturing services for partners | |
| ADME-Tox Solutions | Absorption, distribution, metabolism, excretion and toxicity solutions for preclinical R&D | |
| Partnered clinical pipeline | Drug candidates co-developed with partners, in clinical trials | two projects in Phase II and five in Phase I |
Evotec annual financials
| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | €797.0 million | €781.4 million |
| Research and development | €50.9 million | €68.5 million |
| Net income (loss) | -€196.1 million | -€83.9 million |
| Cash from operations | €18.2 million | €36.4 million |
| Cash and equivalents | €306.4 million | €510.9 million |
| Short-term investments | €90.4 million | €93.2 million |
Questions about Evotec
What is the ticker symbol of Evotec?
Evotec SE trades under the ticker EVT on XETR.
Where is Evotec listed?
Evotec SE is listed on XETR. Our directory also records these other listings: NASDAQ:EVO.
What is the SEC CIK of Evotec?
The SEC Central Index Key (CIK) for Evotec SE is 1412558. Its filings are on SEC EDGAR.
How many shares does Evotec have outstanding?
177,778,907 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-04-08.
Which country or territory is Evotec listed under?
Our directory records Evotec SE under Germany.
What does Evotec do?
Our directory classifies Evotec SE as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline.
What is the ISIN of Evotec?
The ISIN recorded for Evotec SE is DE0005664809.
Does aibio.space cover Evotec?
aibio.space lists Evotec SE among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Evotec incorporated?
SEC records list its state or country of incorporation as 2M.
What does Evotec develop?
Evotec SE is a German company that describes drug discovery, preclinical development and manufacturing as a seamless continuum. It offers access to its platforms to pharmaceutical and biotechnology partners across discovery services, development and manufacturing services, and ADME-Tox solutions.
What is Discovery Services from Evotec?
Discovery Services: Preclinical discovery services offered to pharmaceutical and biotechnology partners
What is Development and Manufacturing Services from Evotec?
Development and Manufacturing Services: Preclinical development and biologics manufacturing services for partners
Is Evotec a smaller reporting company?
SEC records list Evotec SE's filer category as: Large accelerated filer.
Where is Evotec headquartered?
SEC records list its business address as ESSENER BOGEN 7, HAMBURG, 22419.
When does Evotec's fiscal year end?
Evotec SE's fiscal year ends on December 31, per SEC records.
Investor discussion: Evotec
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Stock chart
SEC filings and registration
- SEC name
- Evotec SE
- CIK
- 1412558
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- EVO (Nasdaq), EVOTF (OTC)
- State or country of incorporation
- 2M
- Fiscal year ends
- December 31
- Filer category
- Large accelerated filer
- Business address
- ESSENER BOGEN 7, HAMBURG, 22419
- Phone
- 49-40-560-810
- Shares outstanding
- 177,778,907 as of 2025-12-31 (20-F filed 2026-04-08)
- Former names
- Evotec AG
Recent filings
Listing details
- Company
- Evotec SE
- Ticker
- EVT
- Listing
- XETR
- Country or territory
- Germany
- Business scope
- Biopharma / pharmaceuticals
- ISIN
- DE0005664809
- Other listed symbols
- NASDAQ:EVO
- Last quote in directory
- 2026-10-22
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction